Please login to the form below

Not currently logged in
Email:
Password:

Ocrevus

This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.

EMA clears BMS’ oral multiple sclerosis drug Zeposia

EMA clears BMS’ oral multiple sclerosis drug Zeposia

On the injectable/infusion side, Roche’s anti-CD20 antibody Ocrevus (ocrelizumab) is already a big seller with sales of $3.8bn last year, and has just been approved by the

Latest news

More from news
Approximately 19 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    To succeed, it will have to differentiate from its main direct competitor, the anti-CD20 monoclonal antibody Ocrevus, which has the first-to-market advantage, has labelled indications covering 95% of ... Even if bettering Ocrevus appears unlikely, the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics